Mantle cell lymphoma (MCL) is a rare form of B-cell non-Hodgkin lymphoma (NHL). It is a type of blood cancer that affects white blood cells called lymphocytes. Lymphocytes are white blood cells which help fight infections and other diseases in the body. The disease gets its name because it affects lymphocytes in the mantle zone of a lymph node. Lymphocytes are found mostly in the lymphatic system, which includes lymph nodes, spleen, and bone marrow. MCL cells can spread to other lymph nodes or tissues, such as the gastrointestinal tract, liver, and marrow. A study published by the Leukemia and Lymphoma Society revealed that about 70,800 new cases of NHL were reported in the U.S. in 2014, with only 6% cases (about 4,200) of MCL. It is diagnosed more often in men than women. Caucasian men and women are at a higher risk than men and women of color. MCL occurs mostly in older population and the average age in which cases are diagnosed is mid-60s. Common symptoms of the disease include abdominal pain or bloating, fever, loss of appetite & weight loss, nausea and/or vomiting, night sweats, indigestion, and feeling discomfort. The type of treatment for a patient suffering from MCL depends on various factors such as age, overall health of the patient, and disease stage.
The global mantle cell lymphoma treatment market is projected to grow at a rapid pace in the next few years due to rise in the number of people suffering from mantle cell lymphoma and increase in research and development activities in the health care sector resulting in a favorable product pipeline. A study published in Cancer Journal for Clinicians indicated that 3,320 new cases of MCL were diagnosed in the U.S. in 2016. Approvals for various new drugs by federal agencies is expected to drive the global mantle cell lymphoma treatment market. For instance, in May 2018, the FDA approved AstraZeneca’s Calquence (Acalabrutinib) for relapsed or refractory mantle-cell lymphoma in adults. The mantle cell lymphoma treatment market is also driven by development of targeted therapy drugs with low toxicity in combination with approved drugs for the treatment of relapsed mantle cell lymphoma. However, side effects of these drugs such as neutropenia, anemia, and diarrhea are likely to restrain the global mantle cell lymphoma treatment market.
The global mantle cell lymphoma treatment market can be segmented based on type of therapy, route of administration, end-user, and region. In terms of type of therapy, the mantle cell lymphoma treatment market can be categorized into targeted therapy, chemotherapy, biologics, and radiotherapy. Based on route of administration, the global mantle cell lymphoma treatment market can be bifurcated into oral and intravenous. In terms of end-user, the mantle cell lymphoma treatment market can be divided into hospitals and clinics.
Based on region, the global mantle cell lymphoma treatment market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is projected to lead the global mantle cell lymphoma treatment market during the forecast period. The region’s dominance is attributed to rise in prevalence of mantle cell lymphomas and increase in health care awareness among people about early diagnosis. Moreover, the FDA is focusing on rare diseases, including mantle cell lymphoma, by granting accelerated approvals, breakthrough designations, and orphan drug designations to make treatments available for patients with rare diseases. Asia Pacific and Europe are expected to be the other major markets owing to increase in government initiatives and rise in research and development activities.
Key players operating in the global mantle cell lymphoma treatment market include Bristol-Myers Squibb, GlaxoSmithKline plc, Amgen, Inc., Celgene Corporation, Eli Lilly and Company, AbbVie, Inc., F. Hoffmann-La Roche AG, Bayer AG, Kite Pharma (Gilead Sciences, Inc.), and Johnson & Johnson.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.
TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.
Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:
Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.
Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.
Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.